1316215-12-9 Usage
Description
ACY-241 is an inhibitor of histone deacetylase 6 (HDAC6; IC50 = 2.6 nM). It is selective for HDAC6 over HDAC1-3, HDAC7, and HDAC9 (IC50s = 35, 45, 46, 7,300, and 137 nM, respectively), as well as HDAC4, HDAC5, and HDAC9 (IC50 = >20,000 nM for all). It reduces proliferation of A2780, TOV-21G, and MDA-MB-231 cells when used at a concentration of 3 μM and completely inhibits it and induces apoptosis at a concentration of 10 μM. ACY-241, when used in combination with paclitaxel , inhibits proliferation in MiaPaCa-2, TOV-21G, and T47D cells. It also reduces tumor growth in a MiaPaCa-2 mouse xenograft model when administered at a dose of 50 mg/kg in combination with paclitaxel. ACY-241, in combination with the somatostatin receptor agonist pasireotide , reduces hepatorenal cystogenesis in a rat model of polycystic liver disease.
references
[1]. quayle sn, almeciga-pinto i, tamang d, et al. selective hdac inhibition by ricolinostat (acy-1215) or acy-241 synergizes with imid? immunomodulatory drugs in multiple myeloma (mm) and mantle cell lymphoma (mcl) cells. in: proceedings of the 106th annual meeting of the american association for cancer research, 2015, philadelphia, pa. philadelphia (pa): aacr; cancer res 2015;75(15 suppl):abstract nr 5380. [2]. huang p, almeciga-pinto i, jordan m, et al. selective hdac inhibition by acy-241 enhances the activity of paclitaxel in solid tumor models. in: proceedings of the 2015 aacr-nci-eortc international conference on molecular targets and cancer therapeutics; 2015 nov 5-9; boston, massachusetts. philadelphia (pa): aacr
Check Digit Verification of cas no
The CAS Registry Mumber 1316215-12-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,1,6,2,1 and 5 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1316215-12:
(9*1)+(8*3)+(7*1)+(6*6)+(5*2)+(4*1)+(3*5)+(2*1)+(1*2)=109
109 % 10 = 9
So 1316215-12-9 is a valid CAS Registry Number.
1316215-12-9Relevant articles and documents
METHODS OF USE AND PHARMACEUTICAL COMBINATIONS COMPRISING HISTONE DEACETYLASE INHIBITORS AND JAK 1 2 INHIBITORS
-
Page/Page column 27-28, (2019/06/17)
The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a JAK1/2 inhibitor for the treatment of a cancer, such as a hematological cancer, in a subject in need thereof. Also provided herein are methods for treating a cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a JAK1/2 inhibitor.
PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A PROGRAMMED DEATH-LIGAND 1 (PD-L1) INHIBITOR AND METHODS OF USE THEREOF
-
, (2018/06/12)
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USE THEREOF
-
Page/Page column 30; 32, (2018/06/12)
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
